Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Palantir Shares Face Intense Selling Pressure

Dieter Jaworski by Dieter Jaworski
November 21, 2025
in AI & Quantum Computing, Analysis, Tech & Software
0
Palantir Stock
0
SHARES
80
VIEWS
Share on FacebookShare on Twitter

While artificial intelligence optimism continues to fuel many technology stocks, Palantir investors are confronting a starkly different reality. The data analytics specialist finds itself under significant pressure even as sector leader Nvidia posts record-breaking results and receives widespread acclaim. With prominent billionaires rapidly exiting positions and market analysts sounding alarms, investors face a critical question: Is this merely a temporary correction or the beginning of a more substantial downturn?

Stellar Performance Fails to Impress Markets

The current decline appears paradoxical when examining Palantir’s recent operational achievements. Earlier in November, the company delivered impressive quarterly results featuring a 63 percent revenue surge and dramatically expanding profits. Market reaction, however, demonstrates that perfection had already been priced into the stock. Even Nvidia’s outstanding numbers, which typically lift the entire sector, have failed to support Palantir’s valuation. The shares have decoupled from the broader AI rally, contending with a pronounced correction reflected in weekly losses exceeding 11 percent.

Institutional Investors Retreat En Masse

The primary catalyst behind the current price deterioration appears to be a massive withdrawal of confidence from institutional investors often referred to as “smart money.” Recent disclosures reveal that major financial players have dramatically scaled back their holdings. Israel Englander’s Millennium Management liquidated nearly its entire stake during the third quarter, slashing its position by a staggering 91 percent. Similarly, D.E. Shaw & Co. sold millions of shares, reducing its exposure by 41 percent. These influential investors seem to be reallocating capital toward other financial technology and artificial intelligence opportunities, creating substantial selling pressure.

Should investors sell immediately? Or is it worth buying Palantir?

Valuation Concerns Mount

Compounding the institutional exodus, market experts are adding fuel to the fire with downgraded recommendations. One notable reduction to “Hold” status has further dampened market sentiment. The core issue isn’t operational performance but valuation—at points trading at 102 times revenue, Palantir stood as the most expensive component within the S&P 500 index. Additional psychological pressure comes from “Big Short” legend Michael Burry, whose bearish position has increased anxiety among retail investors. Concerns are mounting that the company’s market valuation has become disconnected from its fundamental business metrics.

Technical Outlook Remains Challenging

From a technical analysis perspective, support levels are weakening. Having fallen below key moving averages, the stock now faces a crucial test of investor confidence. With no new financial results expected in the immediate future, share price movements will likely reflect broader market sentiment rather than company-specific developments. Market participants are watching closely to determine whether value-oriented investors will return or whether fears of an AI sector bubble will dominate trading patterns in the coming weeks.

Ad

Palantir Stock: Buy or Sell?! New Palantir Analysis from March 25 delivers the answer:

The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Palantir: Buy or sell? Read more here...

Tags: Palantir
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Take-Two Stock
Earnings

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock
Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Next Post
Standard Lithium Stock

Lithium Sector Plunges as Chinese Market Intervention Sparks Selloff

Akamai Stock

Akamai Shares Surge on Strong Earnings and AI-Driven Strategy

American Electric Power Stock

American Electric Power: A Stock Caught Between Competing Forces

Recommended

BigBearai Holdings Stock

BigBear.ai Faces Critical Test as Revenue Plummets and Losses Mount

6 months ago
D-Wave Quantum Stock

D-Wave Quantum: CFO’s Multi-Million Dollar Exit Amidst Major Capital Raise

4 months ago
Brightcove Stock

Bending Spoons Forges AI-Powered Streaming Future with Brightcove at the Core

6 months ago
Microsoft Stock

Microsoft Faces Critical Earnings Test Amid AI Expectations

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

Trending

Bionxt Solutions Stock
Healthcare

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

by SiterGedge
March 25, 2026
0

BioNxt Solutions has formally initiated the commercial phase for its sublingual drug delivery platform, marking a significant...

Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents
  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon
  • Ocugen Shares Slide Despite Positive Clinical Trial Results

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com